On the other hand, predicted IDH-mutant astrocytomas (OS = 3 years) and predicted IDH-mutant and 1p/19q-codeleted oligodendrogliomas (OS = 3.1 years) in the REMBRANDT dataset have significantly shorter median survival than TCGA IDH-mutant astrocytomas (OS = 7.3 years) and 1p/19q-codeleted oligodendroglioma (OS = 11.2 years), respectively. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).